



## Drug Repurposing for Cancer Therapy

Guest Editor:

**Dr. Carlos M. Telleria**

Experimental Pathology Unit,  
Department of Pathology, McGill  
University, Montreal, QC H3A 2B4,  
Canada

Deadline for manuscript  
submissions:

**closed (20 May 2022)**

### Message from the Guest Editor

In this Special Issue, we propose encompassing a series of articles dealing with evidence that supports using compounds for cancer therapy that have already been approved worldwide by healthcare systems to treat other diseases or conditions. Many drugs and natural compounds used for particular purposes have shown indirect beneficial effects against cancer initiation, progression, and/or metastasis as single agents or in combination with standard chemo and/or radiotherapy. For example, the treatment of patients with metformin, originally developed for type II diabetes, has reduced the incidence of breast cancer and has led to the study of metformin as an anti-cancer agent.

### Keywords

- cancer therapy
- drug repositioning
- drug repurposing
- old drugs for new uses
- new drugs
- natural compounds
- small molecules
- alternative therapies
- new indications
- multi-targeted drugs
- “off-patent” drugs





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)